S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
This Stock Could Go Up 66% or More. (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
This Stock Could Go Up 66% or More. (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
This Stock Could Go Up 66% or More. (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
This Stock Could Go Up 66% or More. (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
OTCMKTS:SPHDF

Santhera Pharmaceuticals (SPHDF) News Today

$10.29
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$10.29
$10.29
50-Day Range
$0.68
$10.29
52-Week Range
$0.68
$1.20
Volume
N/A
Average Volume
3,788 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SourceHeadline
seekingalpha.com logoSanthera Pharmaceuticals reports 1H results
seekingalpha.com - September 8 at 5:50 AM
finance.yahoo.com logoSanthera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The Corner
finance.yahoo.com - September 8 at 5:50 AM
finance.yahoo.com logoSanthera Announces Half-Year 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - September 7 at 2:52 AM
benzinga.com logoSanthera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
benzinga.com - July 31 at 10:30 AM
markets.businessinsider.com logoH.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)
markets.businessinsider.com - July 31 at 10:30 AM
finanznachrichten.de logoSanthera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share Split
finanznachrichten.de - June 29 at 1:27 AM
finance.yahoo.com logoSanthera Publishes Timeline of the Reverse Share Split
finance.yahoo.com - June 29 at 1:27 AM
finanznachrichten.de logoSanthera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General Meeting
finanznachrichten.de - June 27 at 12:51 PM
finance.yahoo.com logoShareholders Approve all Board Proposals at Today’s Annual General Meeting
finance.yahoo.com - June 27 at 12:51 PM
msn.com logoCatalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
msn.com - June 21 at 9:55 AM
finance.yahoo.com logoCatalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
finance.yahoo.com - June 20 at 7:03 AM
markets.businessinsider.com logoSanthera Grants North America License For Vamorolone To Catalyst Pharma
markets.businessinsider.com - June 20 at 1:46 AM
finance.yahoo.com logoSanthera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties
finance.yahoo.com - June 20 at 1:46 AM
finance.yahoo.com logoSanthera Publishes Agenda for its Annual General Meeting
finance.yahoo.com - June 6 at 4:19 AM
seekingalpha.com logoSanthera Pharmaceuticals GAAP EPS of -CHF1.17
seekingalpha.com - June 2 at 10:21 AM
finanznachrichten.de logoSanthera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022
finanznachrichten.de - June 1 at 10:18 AM
finance.yahoo.com logoSanthera Publishes Annual Report 2022
finance.yahoo.com - May 31 at 7:41 PM
thestreet.com logoSanthera -- A Duchenne Drug With Positive Study Results That Few Know About
thestreet.com - May 24 at 8:06 AM
thestreet.com logoSanthera Drug Wins European Approval for Rare Blindness Disease
thestreet.com - May 13 at 12:18 AM
finance.yahoo.com logoSanthera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update
finance.yahoo.com - April 27 at 9:35 AM
finanznachrichten.de logoSanthera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completed
finanznachrichten.de - April 25 at 9:42 AM
finance.yahoo.com logoVamorolone NDA mid-cycle review meeting by FDA completed
finance.yahoo.com - April 25 at 9:42 AM
finance.yahoo.com logoSanthera Pharmaceuticals Holding AG (VTX:SANN) Is Expected To Breakeven In The Near Future
finance.yahoo.com - April 1 at 2:39 AM
barrons.com logoSanthera Pharmaceuticals Holding AG
barrons.com - March 30 at 2:11 PM
finance.yahoo.com logoSanthera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy
finance.yahoo.com - March 2 at 1:49 AM
finance.yahoo.com logoSanthera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone
finance.yahoo.com - February 8 at 1:27 AM
finanznachrichten.de logoSanthera Pharmaceuticals Holding AG: Santhera enters into CHF 5 million share exchange agreement
finanznachrichten.de - January 10 at 8:39 AM
finance.yahoo.com logoSanthera enters into CHF 5 million share exchange agreement
finance.yahoo.com - January 10 at 8:39 AM
finance.yahoo.com logoSanthera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy
finance.yahoo.com - January 9 at 9:05 AM
technews.tmcnet.com logoSanthera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meeting
technews.tmcnet.com - November 29 at 8:31 PM
finance.yahoo.com logoSanthera Calls Extraordinary General Meeting to Seek Approval for Further Financings
finance.yahoo.com - November 4 at 10:49 AM
finance.yahoo.com logoSanthera Announces Half-Year 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - October 31 at 2:16 AM
finance.yahoo.com logoEuropean Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy
finance.yahoo.com - October 31 at 2:16 AM
finance.yahoo.com logoSanthera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
finance.yahoo.com - October 27 at 5:31 AM
finance.yahoo.com logoSanthera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congress
finance.yahoo.com - October 10 at 3:14 AM
uk.investing.com logoSanthera Pharmaceuticals Holding AG (SANN)
uk.investing.com - October 6 at 4:11 AM
nasdaq.com logoSanthera Submits MAA For Vamorolone In Europe To Treat Duchenne Muscular Dystrophy
nasdaq.com - October 3 at 7:58 AM
finance.yahoo.com logoSanthera Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy
finance.yahoo.com - October 3 at 1:55 AM
finance.yahoo.com logoSanthera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October
finance.yahoo.com - September 29 at 2:38 AM
finance.yahoo.com logoJAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy
finance.yahoo.com - September 1 at 5:02 AM
finance.yahoo.com logoSanthera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy
finance.yahoo.com - August 22 at 1:10 AM
finance.yahoo.com logoSanthera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
finance.yahoo.com - June 30 at 6:33 PM
finanznachrichten.de logoSanthera Pharmaceuticals Holding AG: Santhera Updates on Ongoing NDA Submission for Vamorolone
finanznachrichten.de - June 29 at 3:49 AM
finance.yahoo.com logoSanthera Updates on Ongoing NDA Submission for Vamorolone
finance.yahoo.com - June 29 at 3:49 AM
finanznachrichten.de logoSanthera Pharmaceuticals Holding AG: Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board
finanznachrichten.de - June 28 at 10:49 PM
finance.yahoo.com logoSanthera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board
finance.yahoo.com - June 27 at 6:17 PM
finance.yahoo.com logoSanthera Reports 2021 Annual Results
finance.yahoo.com - June 10 at 2:56 AM
finanznachrichten.de logoSanthera Pharmaceuticals Holding AG: Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference
finanznachrichten.de - June 9 at 1:50 AM
apnews.com logoSanthera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference
apnews.com - June 9 at 1:50 AM
finance.yahoo.com logoSanthera Announces Corporate Calendar Update
finance.yahoo.com - June 3 at 3:37 PM
Get Santhera Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter.



SPHDF Media Mentions By Week

SPHDF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SPHDF
News Sentiment

0.00

0.52

Average
Medical
News Sentiment

SPHDF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SPHDF Articles
This Week

0

0

SPHDF Articles
Average Week

Get Santhera Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (OTCMKTS:SPHDF) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -